{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:26:21Z","timestamp":1780946781641,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115834","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:40:49Z","timestamp":1698792049000},"page":"115834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques"],"prefix":"10.1016","volume":"238","author":[{"given":"Orwa","family":"Siddig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdulbagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-jun","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115834_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.jpba.2023.115834_bib2","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/00498254.2011.603388","article-title":"Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats","volume":"41","author":"Lee","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2023.115834_bib3","unstructured":"Maruyama, M. SAR study, synthesis, and biological activity of lurasidone hydrochloride (LATUDA (R)): New treatment drug for schizophrenia. In Abstracts of Papers of The American Chemical Society. 2012. Amer Chemical Soc 1155 16TH ST, NW, WASHINGTON, DC 20036 USA."},{"issue":"10","key":"10.1016\/j.jpba.2023.115834_bib4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1517\/17460441.2013.815163","article-title":"The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia","volume":"8","author":"Tarazi","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jpba.2023.115834_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2023.115834_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2013.07.013","article-title":"Forced degradation and impurity profiling: recent trends in analytical perspectives","volume":"86","author":"Jain","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115834_bib7","unstructured":"Guideline, I.J.Q.A., current step, Stability testing of new drug substances and products. 2003. 4(1\u201324)."},{"key":"10.1016\/j.jpba.2023.115834_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpba.2015.05.018","article-title":"Identification and characterization of related substances in pomalidomide by hyphenated LC\u2013MS techniques","volume":"114","author":"Lu","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115834_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpba.2017.03.067","article-title":"Identification and characterization of process-related substances and degradation products in apremilast: process optimization and degradation pathway elucidation","volume":"141","author":"Lu","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115834_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114764","article-title":"Identification of degradation products in flumazenil using LC-Q-TOF\/MS and NMR: degradation pathway elucidation","volume":"215","author":"Jiang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115834_bib11","unstructured":"Khan, Z.G., B.S. Vaidehi, G.N. Sarang, G.B. Shivam, P.B. Patil, Second Order Derivative Spectrophotometric Method for Estimation of Lurasidone in Bulk and Pharmaceutical Formulation."},{"issue":"12","key":"10.1016\/j.jpba.2023.115834_bib12","first-page":"305","article-title":"RP-HPLC method development and validation for the analyisis of lurasidone in pharmaceutical dosage forms","volume":"3","author":"Damodar","year":"2011","journal-title":"Drug Invent. Today"},{"key":"10.1016\/j.jpba.2023.115834_bib13","first-page":"4","article-title":"Development and validation of spectrophotometric method for estimation of lurasidone hydrochloride: a novel antipsychotic drug in bulk and pharmaceutical dosage form","volume":"3","author":"Joshi","year":"2012","journal-title":"J. Pain Symptom Manag."},{"issue":"2","key":"10.1016\/j.jpba.2023.115834_bib14","first-page":"327","article-title":"Development and validation of RP-HPLC method for estimation of lurasid one hydrochloride in bulk and pharmaceutical dosage form","volume":"4","author":"Polawar","year":"2014","journal-title":"Int. J. Res. Pharm. Chem."},{"issue":"7","key":"10.1016\/j.jpba.2023.115834_bib15","first-page":"453","article-title":"Novel analytical method development and validation for the quantitative analysis of lurasidone hydrochloride in bulk and pharmaceutical dosage forms by rp-hplc","volume":"3","author":"Ravisankar","year":"2014","journal-title":"World J. Pharm. Res."},{"issue":"23","key":"10.1016\/j.jpba.2023.115834_bib16","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1080\/00397911.2015.1074695","article-title":"Enantioselective synthesis of ((1 R, 2 R)-cyclohexane-1, 2-diyl) bis (methylene) dimethanesulfonate, a lurasidone hydrochloride intermediate","volume":"45","author":"Ravi Ganesh","year":"2015","journal-title":"Synth. Commun."},{"issue":"2","key":"10.1016\/j.jpba.2023.115834_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5958\/2231-5691.2015.00015.5","article-title":"Development and validation of UV spectrophotometric method for estimation of lurasidone in bulk and pharmaceutical formulations","volume":"5","author":"Sri","year":"2015","journal-title":"Asian J. Pharm. Res."},{"issue":"1","key":"10.1016\/j.jpba.2023.115834_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18579\/jpcrkc\/2015\/14\/1\/78370","article-title":"Stability indicating RP-HPLC method for determination and validation of lurasidone HCL in bulk and pharmaceutical dosage forms","volume":"14","author":"Suneetha","year":"2015","journal-title":"J. Pharm. Res."},{"issue":"4","key":"10.1016\/j.jpba.2023.115834_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.12991\/mpj.2017.32","article-title":"Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals","volume":"21","author":"Karaca","year":"2017","journal-title":"Marmara Pharm. J."},{"key":"10.1016\/j.jpba.2023.115834_bib20","doi-asserted-by":"crossref","unstructured":"Krishna, M.R., S.P. Kumar, M. Khurdhus, G. Vaishnavi, M. Mamatha, K. Ravi, A Novel Spectrophotometric Method for The Estimation of Lurasidone in Pharmaceutical Dosage Forms. 2017.","DOI":"10.20959\/wjpps20177-9474"},{"key":"10.1016\/j.jpba.2023.115834_bib21","unstructured":"Kasyap, A.S., K. Vijayasri, RP-HPLC Method Development and Validation of Lurasidone HCl in Bulk and Pharmaceutical Dosage Form. 2018."},{"issue":"4","key":"10.1016\/j.jpba.2023.115834_bib22","first-page":"750","article-title":"Development of a method for quantification of two genotoxic impurities in lurasidone using LC-MS\/MS","volume":"54","author":"Venu","year":"2019","journal-title":"J. Chem. Technol. Metall."},{"issue":"11","key":"10.1016\/j.jpba.2023.115834_bib23","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.52711\/0974-360X.2022.00840","article-title":"Development and validation of RP-HPLC method for estimation of lurasidone and its impurities Lurasidone 1 and Lurasidone 8","volume":"15","author":"Vaja","year":"2022","journal-title":"Res. J. Pharm. Technol."},{"issue":"6","key":"10.1016\/j.jpba.2023.115834_bib24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/dta.1698","article-title":"The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography\u2010tandem mass spectrometry","volume":"7","author":"Patteet","year":"2015","journal-title":"Drug Test Anal."},{"issue":"7","key":"10.1016\/j.jpba.2023.115834_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/bmc.3651","article-title":"LC\u2010MS\/MS assay for the determination of lurasidone and its active metabolite, ID\u201014283 in human plasma and its application to a clinical pharmacokinetic study","volume":"30","author":"Katteboina","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"12","key":"10.1016\/j.jpba.2023.115834_bib26","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/bmc.1625","article-title":"Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high\u2010performance liquid chromatography with tandem mass spectrometry","volume":"25","author":"Koo","year":"2011","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115834_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10337-012-2294-5","article-title":"A sensitive and selective LC-MS method for the determination of lurasidone in rat plasma, bile, and urine","volume":"75","author":"Chae","year":"2012","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2023.115834_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2014.11.035","article-title":"Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC\/ESI\/QTOF\/MS\/MS","volume":"105","author":"Talluri","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2023.115834_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jms.4871","volume":"57","author":"Wang","year":"2022","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115834_bib30","unstructured":"International Conference on Harmonisation (ICH) Guideline, Q2 (R1): Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonisation, Geneva, Switzerland (2005)."},{"key":"10.1016\/j.jpba.2023.115834_bib31","unstructured":"International Conference on Harmonisation (ICH) Guideline. Pharmaceutical Development Q8 (2R) (2009)."},{"key":"10.1016\/j.jpba.2023.115834_bib32","series-title":"Advances and Challenges in Pharmaceutical Technology","first-page":"243","article-title":"Chapter 8 - Process analytical technology (PAT) tools: Uses in pharmaceutical manufacturing","author":"Das","year":"2021"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:32:31Z","timestamp":1760002351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523006039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"alternative-id":["S0731708523006039"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115834","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115834"}}